CELZ Creative Medical Technology Holdings Inc

Not all regenerative approaches to chronic lower back pain target the same stage of disease — or use the same delivery approach. Olastrocel is being developed for patients with degenerative disc disease and is administered through an ultrasound-guided intramuscular injection, rather than being injected directly into the spinal disc. That distinction matters: $CELZ is evaluating an approach designed to address the condition without requiring intradiscal administration. As Olastrocel moves through follow-up and data maturation, its differentiated clinical approach remains a key part of the program’s development story. Different approach. Different delivery. A clinical program is moving toward its next stage. $CELZ

$CELZ Long-term shareholders have understood the breadth of CELZ-201's potential for years. That isn't the issue. The issue is execution and capital allocation. Shareholders have watched the stock lose roughly 99% of its value, endured reverse splits and substantial dilution, while senior executives/directors have received millions in compensation and company capital has been directed into unrelated investments and related-party ventures. Meanwhile, Olastrocel is supposedly the lead asset approaching Phase 3, yet shareholders still have no meaningful Phase 3 budget, financing plan, regulatory roadmap or clear explanation of what capital will be required to get there. “One cell platform. Multiple development paths” sounds attractive. But CELZ does not suffer from a shortage of possibilities. It suffers from a shortage of accountability, prioritization and clearly communicated execution plans.

Olastrocel may be leading the $CELZ story in lower back pain-but CELZ-201 is being developed beyond a single indication. Alongside the ADAPT program, CELZ-201 is being evaluated in the FDA-cleared Phase 1/2 CREATE-1 trial for new-onset Type 1 Diabetes. The Company is also using CELZ-201 in preclinical studies focused on abnormal glucose tolerance and the prevention of Type 1 Diabetes in high-risk individuals. One cell platform. Multiple development paths. For $CELZ, that means the technology behind its lead clinical asset has potential applications extending beyond the program currently leading the story.

$CELZ Is there any movement in this chat towards a lawsuit against management at this point? CEOs compensation is well outsized vs deployment of capital into the business. No communication. Investor relations unresponsive…

Why did $CELZ increase its ownership in BioDefense? Through the September transaction, CELZ acquired an additional 20% interest in BioDefense, bringing its total ownership to 80%. This increases CELZ’s participation in BioDefense as its research and technology programs advance, adding another potential source of long-term value alongside its lead clinical program. The transaction also broadens CELZ’s exposure to emerging applications of its regenerative medicine and biotechnology capabilities.

$CELZ shareholders- Would YOU approve this use of company funds? CELZ's board approved Bionance, under which CELZ committed up to $500K to invest in publicly traded securities. Its first disclosed investment? $54K in convertible debt and warrants of Applife Digital Solutions, a distressed OTC-traded automotive-parts company whose filings raised substantial doubt about its ability to continue operating. CELZ supplied $43,200. The note carries a 12% interest charge and can convert at 65% of the LOWEST traded price over the prior 10 trading days. Bionance's managing entity, owned equally by Warbington, Dickerson and Patel, is entitled to 30% of distributions AFTER the other members recover their contributed capital. (how much of CELZ have they actually bought 🤦‍♂️?) CELZ still faces substantial costs advancing Olastrocel toward Phase 3. Directors Snow, Finger and Urdang: Why did the board approve this? What alternatives did you consider? How does it serve shareholders?

$CELZ In an 8-K dated Sept 24, 2026, CELZ bought 4,000,000 BioDefense shares from Creative Acquisition Corp. for $200,000 in cash plus 1,000,000 CELZ shares, leaving CELZ with 80% of BioDefense and CAC with 20%. (sec) In the Schedule 13D dated Oct 1, 2026, Warbington is CELZ's President and CEO and also Chairman and CEO of CAC, which is a holding company. So he sits on both sides of the deal, which is the legitimate governance concern. (sec)

$CELZ $CELZ So in a few words warbington it's a white collar criminal? There's no future with this scam

$CELZ FYI for retail shareholders regarding CEO Timothy Warbington's recent Schedule 13D filing & ownership structure: Timothy Warbington now controls a 13.7% beneficial stake (1,034,904 shares) following the latest BioDefensé, Inc. transaction. While presented as a pipeline consolidation, it is important to understand the related-party mechanics: The Payout: $CELZ handed over $200,000 in cash plus 1,000,000 restricted shares of CELZ common stock to Creative Acquisition Corp. (CAC). The Catch: Warbington 100% owns and controls CAC. The cash and stock went straight to his private entity. • Pattern of Play: This follows similar insider setups, like late 2025's Bionance Management LLC structure (where Warbington's entity gets a 30% cut of investment distributions). While legally disclosed, this is heavy insider self-dealing. The CEO gets guaranteed cash upfront, while retail investors hold the bag on speculative, unproven pipelines. Know what you own!

$CELZ Interesting that the “Official CELZ Representative” is posting promotional content while substantive shareholder questions remain unanswered. I have repeatedly tried to get answers through the company’s stated IR channels. I was told my questions would be forwarded. I am still waiting. CELZ says “data transparency” is one of the principles guiding the company. Transparency cannot mean publishing marketing about Olastrocel while ignoring reasonable questions about capital allocation, dilution, related-party transactions, executive compensation and the Phase 3 roadmap. If IR has time to market the company on social media, it has time to answer shareholders.

$CELZ No control group clowns lmfao. Attribute this 'IMPROVEMENT' to time instead of fufu drugs/injections. Symptoms will improve with time.

$CELZ Every stock that I've seen where management/IR engages retail investors on social media ends up at or near zero...just saying.

$CELZ down, almost thirteen percent in one week.Junk, in my opinion, only i'm gonna start shortening this stuff!

$CELZ FYI According to Creative Medical Technology 2026 (YTD Metrics): His active base contract dictates a $339,720 annual salary, and on July 1, 2026, the board's Compensation Committee authorized an additional $100,000 cash bonus. SEC.gov +2

$CELZ I think Celz holds more patents then ford motor company. How much revenue has been generated from all those patents? Zero

$CELZ I held on to a couple of shares of Celz I bought about 7 years ago on OTC. Just as a reminder that this company is a scam. Always on the edge of a life changing breakthrough that never materializes. By the way after all the RS and delusion over the years my breakeven on the shares I have is over 1000 per share.

$CELZ My last microcap (ARDS) that made a strong retail investment push went dark. Fortunately, I read between the lines and escaped with about 25% of my investment.

⚠️ Have you observed ticker RETO last month going almost 7000% then dropping all the way back? ⚠️ Chinese tickers are getting out of control and destroy all the american short sellers!! I have taken a position in ticker HCAI as I personally see a lot of similarities to ticker RETO. HCAI is going to split on friday into a 350k float and I look forward to sell for a massive profit. Put ticker HCAI on watch. China is getting active again 🎰 🚀🚀 $CELZ xx

$CELZ Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

$CELZ Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study